comparemela.com
Home
Live Updates
Omeros Corporation Reports Interim Data with Alternative Pat
Omeros Corporation Reports Interim Data with Alternative Pat
Omeros Corporation Reports Interim Data with Alternative Pathway Inhibitor OMS906 as Monotherapy in Patients with Paroxysmal Nocturnal Hemoglobinuria
At lowest planned subcutaneous dose, Omeros’ MASP-3 inhibitor OMS906 showed clinically and statistically significant improvements in hemoglobin and LDH, which were seen early and maintained... | April 25, 2023
Related Keywords
,
Omeros Corporation ,
Omeros Corporation Nasdaq ,
Mean Hemoglobin Change ,
Baseline Over Time ,
Business Wire ,
About Omeros ,
Omeros Corporation Stock Exchange ,
News ,
Information ,
Press Release ,
It ,
Lowest ,
Planned ,
Subcutaneous ,
Inhibitor ,
Ms906 ,
Howed ,
Linically ,
End ,
Statistically ,
Significant ,
Improvements ,
N ,
Hemoglobin ,
Which ,
Were ,
Teen ,
Early ,
Nd Omer Us6821431029 ,